All patients undergoing allogeneic or autologous HSCT at the participating centres will be observed. Once a diagnosis of CNS disorder is made, additional data will be reported for these patients. We will identify clinical and diagnostic characteristics such as cerebrospinal fluid (CSF) and neuroimaging patterns, risk factors, response to treatment (including novel antifungal agents such as isavuconazole) and outcome. In addition, risk factors for CNS disorders after allogeneic and autologous HSCT will be analyzed using a prospectively assessed matched control group. In the future, this study might be the basis for an interventional trial (e.g. using a prophylactic approach).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinical characteristics of infectious and non-infectious CNS disorders following allogeneic or autologous HSCT
Timeframe: 32 months
Diagnostic characteristics of infectious and non-infectious CNS disorders following allogeneic or autologous HSCT
Timeframe: 32 months
Efficacy of CNS treatment for different types of CNS disorders
Timeframe: 30 days
Survival
Timeframe: 32 months